Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bambuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.90 |
| ▸ | BCHE | P06276 | 6/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.90 |
| ▸ | ACHE | P22303 | 2/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | CASP7 | P55210 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21674420 | 0.99 | BCHE (0.88) | BCHELMNACYP2D6ACHEADRB2 | |
| Hydrochloric Acid SCHEMBL11123610 | 0.97 | BCHE (0.85) | BCHELMNACYP2D6ACHEADRB2 | |
| Bambuterol SCHEMBL13923751 | 0.95 | BCHE (1.00) | BCHELMNACYP2D6ACHEADRB2 | |
| Bambuterol SCHEMBL4432 | 0.95 | BCHE (1.00) | BCHELMNACYP2D6ACHEADRB2 | |
| Bambuterol SCHEMBL4431 | 0.95 | BCHE (1.00) | BCHELMNACYP2D6ACHEADRB2 | |
| Bambuterol SCHEMBL744580 | 0.94 | BCHE (0.97) | BCHELMNACYP2D6ACHEADRB2 | |
| Bambuterol SCHEMBL1649102 | 0.92 | BCHE (0.95) | BCHELMNACYP2D6ACHEADRB2 | |
| Bambuterol SCHEMBL3713500 | 0.91 | BCHE (0.92) | BCHELMNACYP2D6ACHEADRB2 | |
| SCHEMBL15790253 | 0.90 | BCHE (0.90) | BCHELMNACYP2D6ACHEADRB2 | |
| SCHEMBL15790471 | 0.88 | BCHE (0.85) | BCHELMNACYP2D6ACHEADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290580-A1 | New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | TAN WEN (CN) | 2021-09-23 | — | — | US | claimed |
| WO-2020028124-A1 | NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS | TAN WEN (CN) | 2020-02-06 | — | — | WO | claimed |
| WO-2023015017-A2 | INHIBITION OF BCHE USING (±)-CARBAMATE-β-PHENYLETHANOLAMINE ANALOGUES AND SIRNAS FOR TREATMENT OF NAFLD | WEN TAN (CN) | 2023-02-09 | — | — | WO | disclosed |
| US-20210290580-A1 | New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | TAN WEN (CN) | 2021-09-23 | — | — | US | disclosed |
| CN-113271931-A | New application of carbamate beta phenylethanolamine analogue in enhancing clearance of intracellular LDL cholesterol and combination with statins | 谭文 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020028124-A1 | NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS | TAN WEN (CN) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290580-A1 | New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | CETP, NPC1L1, LDLR | ADRB2 224/4885BCHE 17/4885LMNA 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.